Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and pharmacokinetics study of NMK20 in healthy Japanese male subjects
jRCT2080222333Phase 1
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Dec 2013
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-6240, sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Safety endpoints and Pharmacokinetics and radiation-exposed dose.
02
Drugs
MK-6240
Beyond the preview
Go deeper on jRCT2080222333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222333.